CLOs on the Move

Motus GI

www.motusgi.com

 
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.motusgi.com
  • 1301 E. Broward Blvd. Suite 310
    Fort Lauderdale, FL USA 33301
  • Phone: 954.541.8000

Executives

Name Title Contact Details

Similar Companies

Bright Dental USA

Bright Dental USA is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merlin Development Inc

Merlin Development Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VisionQuest Biomedical

VisionQuest Biomedical Inc. is a research and development company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets. VisionQuest has developed multiple medical devices with funding from the National Institutes of Health and is now looking to transfer those technologies to the commercial space. Our devices are currently being used in the United States and Latin America.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.

Avalign Technologies

Avalign Technologies is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.